

NOTICE OF SHARE CONSOLIDATION

Melbourne, Australia – 21 May 2026: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform advises that it intends to undertake a consolidation of capital of the Company (**Consolidation**), subject to the receipt of shareholder approval at its Extraordinary General Meeting to be held on Friday, 19 June 2026.

Under the proposed Consolidation, every 100 fully paid ordinary shares held by shareholders on the Record Date will be consolidated into one (1) fully paid ordinary share.

The purpose of the Consolidation is to reduce the number of securities on issue and thereby create a more appropriate capital structure for the Company. The Board believes the Consolidation may improve the marketability and trading profile of the Company's securities.

The Consolidation will apply equally to all security holders and will not materially affect security holders' percentage ownership interests in the Company, subject to adjustments resulting from the treatment of fractional entitlements.

In accordance with ASX Listing Rule 7.22, the number of unlisted options and Share Appreciation Rights on issue will be consolidated in the same ratio as the ordinary shares, and the exercise price of the unlisted options will be amended in inverse proportion to that ratio.

Where a fractional entitlement arises to a security, the Company will round the fraction up to the nearest whole number.

The Consolidation will take effect in accordance with the following indicative timetable:

Event	Date
Announcement of Share Consolidation and despatch of Notice of EGM	Thursday, 21 May 2026
EGM held and approval of Consolidation announced to ASX	Friday, 19 June 2026
Effective date of Consolidation	Thursday, 25 June 2026
Last day for trading on pre-Consolidation basis	Friday, 26 June 2026
First day for trading on post-Consolidation and deferred settlement basis	Monday, 29 June 2026
Record Date for Consolidation (Last day to register transfers on pre-Consolidation basis)	Tuesday, 30 June 2026
Last day to update register, send post-Consolidation holding statements, announce to ASX that this has occurred and trading on deferred settlement basis ends (if before noon Sydney time)	Tuesday, 7 July 2026

Trading starts on a normal T+2 basis	Wednesday, 8 July 2026
First settlement of trades conducted on a +deferred settlement basis and on a normal T+2 basis	Friday, 10 July 2026

Note: The timetable is subject to change at the discretion of the Board and in accordance with the ASX Listing Rules and applicable laws.

Further details on the Consolidation, including the information required to be provided to shareholders of the Company under the Corporations Act 2001 (Cth) and the ASX Listing Rules are set out in the Notice of Extraordinary General Meeting dated 21 May 2026.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited

investors@adherium.com

Media Enquiries:

Haley Chartres

HACK Director

haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at

adherium.com